卵巢癌(Epithelial Ovarian Cancer)是妇科最常见的恶性肿瘤之一,病死率居女性生殖系统恶性肿瘤之首。由于卵巢解剖位置隐匿,患者早期症状不明显,因此70%以上的卵巢癌患者在初次就诊时已届晚期(FIGOⅢ期~Ⅳ期)。近年来,尽管治疗手段得到了较大的发展,但是预后仍然较差[1]。目前卵巢癌的标准治疗模式是手术联合术后化疗,即初次肿瘤细胞减灭术(Primary debulking sur- Epithelial Ovarian Cancer is one of the most common malignant tumors in gynecology, with the highest mortality rate among the female genital malignancies. As the ovarian anatomical location of occult, the early symptoms of patients is not obvious, so more than 70% of ovarian cancer patients have advanced at the time of the first visit (FIGO Ⅲ ~ Ⅳ). In recent years, although the treatment has been greatly developed, but the prognosis is still poor [1]. The current standard treatment of ovarian cancer is surgery combined with postoperative chemotherapy, that is, the primary tumor cytoreductive surgery (Primary debulking sur-